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Aim: We have shown that diabetes alters structural and functional
properties of the cerebrovasculature in part by the activation of the
endothelin (ET) system in a glucose-dependent manner. Here, we
tested the hypothesis that established diabetes-induced vascular
dysfunction and remodeling could be reversed by glycemic control or
dual ET-1 receptor antagonism. Methods: Studies were performed in
non-obese type-2 diabetic Goto–Kakizaki (GK) rats. GK rats were
treated with vehicle, metformin (300 mg/kg/day) or dual ET-receptor
antagonist bosentan (100 mg/kg/day) after onset of remodeling from
18 to 22 weeks by oral gavage. Additional groups included vehicle-
treated 10 or 18-week GK rats. Blood glucose and mean arterial blood
pressure (MAP) were monitored weekly. At termination, middle
cerebral artery (MCA) lumen diameter, media thickness (MT), media:
lumen (M:L) ratio, cross-sectional area (CSA) and myogenic-tone
were measured using pressurized arteriograph (n= 8–14/group).
Results: GK MAP was 102, 105 and 119 for vehicle, metformin and
bosentan, respectively. 18 and 22-week diabetic GK rats displayed
increased M:L ratio and CSA, but decreased lumen diameter and
myogenic tone compared to 10-week animals. Glycemic control with
metformin signiﬁcantly improved blood glucose and partially reversed
vascular remodeling by decreasing theMT,M:L ratio and CSA.Myogenic
tonewas improved only at lower pressures. Bosentan improved theMT
and M:L ratio and did not affect CSA. Bosentan showed a signiﬁcant
improvement in MCA myogenic-tone over the pressure range despite
elevated MAP. Conclusions: Glycemic control or ET-1 antagonism can
partially reverse diabetes-induced cerebrovascular remodeling and
dysfunction. These results strongly suggest that either approach offers
a therapeutic beneﬁt and combination treatments need to be tested.
doi:10.1016/j.lfs.2014.01.044
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Aims: Up-regulation of the endothelin (ET) system in type-2 diabetes
leads to increased contraction and decreased relaxation in basilar artery.
We showed that 1) ET receptor antagonism prevents diabetes-mediated
cerebrovascular dysfunction, and 2) glycemic control prevents activation
of the ET system in diabetes. The goal of the current study was to
determine whether and to what extent glycemic control or ET-receptor
antagonism reverses established cerebrovascular dysfunction in diabetes.
Methods: Non-obese type-2 diabetic Goto–Kakizaki (GK) rats were
administered either vehicle, metformin (300 mg/kg/day) or dual ET-
receptor antagonist bosentan (100 mg/kg) for 4 weeks starting at 18-
weeks after established cerebrovascular dysfunction (n= 6–8/group).
Blood glucose and blood pressure were monitored weekly. At termina-
tion, basilar arterieswere collected and cumulative dose–response curves
to ET-1 (1–500 nM), 5-HT (1–1000 nM) and acetylcholine (Ach, 1 nM–
5 μM) were studied by wire myograph. Results: Only metformin
decreased blood glucose. MAP was 102, 105 and 119 for vehicle,
metformin and bosentan, respectively. The magnitude of basilar artery
constriction in response to KCl was similar among groups. Interestingly,
constriction to ET-1 and 5-HT (area under curve, AUC) was greater in
treated animals as compared to vehicle-treated GK rats; however, there
was no difference in Rmax or EC50. Both bosentan and metformin
improved sensitivity to Ach and only bosentan increased relaxation
(Rmax and AUC) despite elevated blood pressure. Conclusion: These
results suggest that augmented contractile response to vasoactive agents
is not improved by glycemic control or ET-receptor antagonism but ET-
receptor antagonism is effective in improving relaxation response even if
started after established cerebrovascular dysfunction and offers thera-
peutic potential.
doi:10.1016/j.lfs.2014.01.045
ETA receptor antagonists in the treatment of diabetic ketoacidosis
Anil Gulatia, Manish_S Lavhaleb, Birinder_S Marwahb, Suresh Havaladc
aMidwestern University, Downers Grove, IL, USA
bPharmazz Research Center, Pharmazz India Private Limited,
Greater Noida, UP, India
cAdvocate Lutheran General Children's Hospital, Park Ridge, IL, USA
E-mail address: agulat@midwestern.edu (A. Gulati)
In patients with type I diabetes mellitus poor management causes a
drastic rise in glucose levels resulting in diabetic ketoacidosis (DKA).
About 1% of DKA episodes can be complicated by cerebral edema. ET
and its receptors are involved in the regulation of cerebral blood ﬂow.
We studied the effect of ETA receptor antagonists in a rat model of DKA.
DKAwas produced by streptozotocin (150 mg/kg, ip). Group 1: Control
(non-diabetic) animals administered citrate. Animals that developed
DKA were divided in ﬁve additional groups. Group II: DKA animals
without treatment; Group III: DKA animals given saline; Group IV: DKA
animals given saline and insulin of 1.5 u/kg/h; Group V: DKA animals
given saline, insulin of 1.5 u/kg/h and BMS-182874 (9 mg/kg); and
Group VI: DKA animals given saline, insulin of 1.5 u/kg/h and BQ123
(1 mg/kg). Blood glucose and ketones markedly increased by day 4 in
DKA rats. Saline/insulin treatment in DKA rats increased the plasma and
brain ET-1 levels which were not affected by BMS-182874 or BQ123
treatment. There was no change in the expression of ETB receptors in
the brain, however, ETA receptor expression increased in DKA rats and
was not altered following treatment with insulin, BMS-182874 or
BQ123. Animals in insulin/saline group showed a signiﬁcant increase
(160%) in cerebral blood perfusion compared to baseline. This increase
in cerebral perfusion was attenuated by BQ123 or BMS-182874.
Treatment with BQ123 also improved blood pH and ketones in DKA
rats. It can be concluded that ETA receptor antagonists maybe of
therapeutic use in the management of DKA and its complications.
doi:10.1016/j.lfs.2014.01.046
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About 50% of male diabetic patients have erectile dysfunction (ED),
which is considered as the vascular and neuropathic complications.
Vascular endothelial growth factor (VEGF) has been extensively
documented for its pathogenic signiﬁcance in different complications
of diabetes andwe reported that VEGF signaling is greatly diminished in
penis in a rat model of type II diabetes. The present study used 3 weeks
duration of streptozotocin (STZ)-induced diabetic (DM) rat model to
assess the VEGF expression with NO system in penile tissue and
concomitantly the effects of endothelin antagonismhas been studied on
these changes. Male Sprague–Dawley rats were administered citrate
saline vehicle or STZ (65 mg/kg IP). One week after the injection,
animals were separated into those receiving endothelin-A/B (ET-A/B)
dual receptor antagonist (SB209670, 1 mg/kg/day), endothelin-A (ET-A)
receptor antagonist (TA-0201, 1 mg/kg/day) or saline for 2 weeks by
osmotic mini pump. The local ET-1 level in DM penis was higher by 20%
than that in non-DM rats. A 30% decrease in VEGF expression in penile
tissue was seen in DM rats. Penile NO and eNOS levels were decreased in
DM rats; greatly restored by ET-A receptor antagonist while unchanged
by ET-A/B dual antagonist. iNOS was not signiﬁcantly changed in penile
tissues among non-DM, DM and ET-A antagonist treated groups. Thus,
we conclude that (1) VEGF and pAkt were downregulated in type 1 DM
penis, and that (2) the ET-A antagonist was potentially effective in
reversing the decreased NO and eNOS levels in DM penis than those by
ET-A/B dual antagonist.
doi:10.1016/j.lfs.2014.01.047
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Aim: To elucidate the pathophysiological signiﬁcance of the endog-
enous oxidized LDL (oxLDL) blocker, which was originally described as
an endothelium-derived secreted protein Del-1 (developmental endo-
thelial locus-1). Background: oxLDL can potentiate the induction of foam
cell formation and inﬂammatory responses, the processes which are
believed to be integral to atherogenesis. However, no endogenous
proteins, which interfere with oxLDL binding to its receptors, have been
identiﬁed. Methods: Interaction between oxLDL and Del-1 was exam-
ined in a cell-free system by ELISA. Inhibition of binding and action of
oxLDL was examined with CHO cells expressing LOX-1 and with COS-7
cells transfected with scavenger receptors. Cultured human umbilical
vein endothelial cells (HUVEC) and THP-1 were also used to analyze the
inhibitory effects of Del-1 on oxLDL action. Results: We found that Del-1
selectively bound to oxLDL, but not to native LDL. Del-1 inhibited the
uptake of DiI-labeled oxLDL (DiI-oxLDL) by LOX-1 expressed in COS-7,
but did not inhibit DiI-labeled native LDL uptake by LDL receptor. Del-1
inhibited DiI-oxLDL binding to other oxLDL receptors aswell, such as SR-
A and CD36. In addition, Del-1 inhibited DiI-oxLDL uptake byHUVEC and
THP-1-derived macrophages. Site-directed mutagenesis revealed that
two arginine residues in Del-1 were crucial for the binding of oxLDL.
Furthermore, Del-1 suppressed oxLDL-induced signal transduction in
LOX-1-expressing CHO cells. In HUVEC, Del-1 also suppressed oxLDL-
induced signaling and endothelin-1 secretion. Thus, we demonstrated
that Del-1 is an endogenous protein which protects cells from oxLDL
actions. Conclusion: We identiﬁed, for the ﬁrst time, an endogenous
oxLDL blocker which may play a regulatory role in interfering
progression of atherosclerosis.
doi:10.1016/j.lfs.2014.01.048
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Purpose: Endothelin-1 contributes to endothelial dysfunction in
patients with atherosclerosis and type 2 diabetes. In healthy arteries the
ETA receptormediates themain part of the vasoconstriction induced by
endothelin-1 while the ETB receptor mediates vasodilatation. The ETB
receptor expression is upregulated in atherosclerosis and may thereby
contribute to the vasoconstrictor tone and development of endothelial
dysfunction. The aim of the present study was to compare the
effects of selective ETA and dual ETA/ETB blockade on endothelial
function in patients with type 2 diabetes and coronary artery disease.
Methods: Twelve patients were included in this cross-over study with
blinded evaluation. Forearm blood endothelium-dependent and endo-
thelium-independent vasodilatation was assessed by venous occlusion
plethysmography during intra-arterial infusions of serotonin and nitro-
prusside, respectively, before and after 60 min of intra-arterial infusion of
either the selective ETA antagonist BQ123 or the combination of BQ123
and the ETB antagonist BQ788. Changes between the two treatments
were compared using 2-way analysis of variance. Results: Dual ETA/ETB
receptor blockade increased baseline forearm blood ﬂow by 30± 14%
(P b 0.01) whereas selective ETA blockade did not (14 ± 8%). Both
selective ETA blockade and dual ETA/ETB blockade induced a 2-fold
increase in endothelium-dependent vasodilatation (P b 0.001). The
improvement in endothelium-dependent vasodilatation did not differ
between the two treatment strategies. Both treatments improved the
endothelium-independent vasodilatation. Conclusions: Both selective
ETA and dual ETA/ETB improve endothelial function in patients with
type 2 diabetes and coronary artery disease. Addition of ETB to ETA
receptor blockade increases basal blood ﬂow but does not additionally
improve endothelial function.
doi:10.1016/j.lfs.2014.01.049
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Background: Statins reduce the incidence of cardiovascular events in
patientswith acutemyocardial infarction (AMI). Although all statins are
equally effective in secondary prevention, there might be certain
differences in the effects of lipophilic and hydrophilic statins and its
associationwith oxidative stress levels in AMI patients remains unclear.
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